In statement on Twitter, Quinn’s agent explains the Dallas defender believes his seizure prevention medication was contaminated with a substance called probenecid, which the NFL classifies as a masking agent under its drug policy. Quinn failed his test on April 2nd, and embarked on an investigation to find out how the substance was in his system.
His team claims Quinn’s pharmacy filled a prescription for probenecid prior to filling Quinn’s prescription, which may have resulted in the contamination. Additionally, Quinn argues that his levels of probenecid would have been much higher had he actually been using the substance as a masking agent.
Quinn has already lost his appeal of the ban, so he’ll be out for the first two games of the regular season. The NFL has historically taken a hard approach on drug suspensions, and successful appeals are rare. Recently, Giants wideout Golden Tate appealed his upcoming suspension by arguing that was he taking fertility drugs, but the leagues’s policy is considered “unforgiving” and “rigid.”
Quinn, for his part, recently underwent surgery to repair two fractures in his hand, but was expected to be back in time for the season opener, according to David Moore of the Dallas Morning News (Twitter link). Now, he’ll get two additional weeks for his hand to heal, but Dallas will have to rely on other defensive ends — such as Taco Charlton and Tyrone Crawford — to rush the passer opposite DeMarcus Lawrence.
The Cowboys acquired Quinn from the Dolphins in March in exchange for a 2020 sixth-round pick. Quinn agreed to lower his salary under the terms of the deal, reducing his compensation from $11.1MM to $8MM. While he finished with only 6.5 sacks in 2018, Quinn tied for 20th among defensive ends with 24 quarterback hits. Pro Football Focus, meanwhile, assigned Quinn the 19th-highest pass-rush grade among 103 qualifying DEs.
Photo courtesy of USA Today Sports Images.